In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

A novel sterically hindered platinum complex, AMD473 [cis-aminedichloro(2-methylpyridine) platinum (II)], has been selected for phase I clinical trials due to commence in 1997. AMD473 was rationally designed to react preferentially with nucleic acids over sulphur ligands such as glutathione. This re...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of cancer Vol. 77; no. 3; pp. 366 - 373
Main Authors:	Holford, J, Sharp, SY, Murrer, BA, Abrams, M, Kelland, LR
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.02.1998 Nature Publishing Group
Subjects:	Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Cisplatin - pharmacokinetics Cisplatin - pharmacology DNA - metabolism Drug Resistance Drug Resistance, Neoplasm Epidemiology experimental-oncology General aspects Glutathione - metabolism Humans Medical sciences Molecular Medicine Oncology Organoplatinum Compounds - pharmacology Pharmacology. Drug treatments Tumor Cells, Cultured Tumor Suppressor Protein p53 - biosynthesis Antineoplastic agent Human Carcinoma Cytotoxicity Malignant tumor In vitro Cisplatin Female genital diseases Ovarian diseases Ovary Established cell line Reversibility Negative therapeutic reaction Platinum II Complexes
ISSN:	0007-0920, 1532-1827
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!